Free shipping on all orders over $ 500

Briakinumab

Cat. No. M25215

All AbMole products are for research use only, cannot be used for human consumption.

Briakinumab Structure
Synonym:

ABT-874

Size Price Availability Quantity
100ug USD 240 In stock
1mg USD 480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Chemical Information
CAS Number 339308-60-0
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Benjamin Misselwitz, et al. Digestion. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More

[2] Remo Panaccione, et al. Inflamm Bowel Dis. Briakinumab for treatment of Crohn's disease: results of a randomized trial

[3] Pawel Traczewski, et al. BioDrugs. Briakinumab for the treatment of plaque psoriasis

[4] Mona Gandhi, et al. Semin Cutan Med Surg. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis

[5] Xinaida Taligare Lima, et al. Expert Opin Biol Ther. Briakinumab

Related IL Receptor/Related Products
Reslizumab

Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin 5 (IL-5) for the study of eosinophilic asthma. Reslizumab effectively blocks il-5 function. Reslizumab inhibited IL-5-dependent cell proliferation with an IC50 of about 91.1 pM.

Montelukast sodium

Montelukast sodium selectively antagonizes leukotriene D 4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1.

VGX-1027

VGX-1027 is an orally active immunomodulator.

Diacerein

Diacerin is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.

SC144

SC144 is the first oral active GP130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, eliminates Stat3 phosphorylation and nuclear translocation, and further inhibits downstream target gene expression. SC144 inhibited signal transduction induced by GP130 ligand. SC144 induces apoptosis of human ovarian cancer cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Briakinumab, ABT-874 supplier, IL Receptor/Related, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.